Ahram Online

The Egyptian Drug Authority approves the launch of “Trelegy Ellipta” — a new hope for patients with chronic obstructive pulmonary disease (COPD) and asthma.

The global pharmaceutical company GSK announced the launch of “Trelegy Ellipta” following the approval of the Egyptian Drug Authority. Trelegy represents a new breakthrough in the treatment of chronic ...
Pharmabiz

US FDA approves GSK & Innoviva’s Trelegy Ellipta as first once-daily single inhaler triple therapy to treat both asthma and COPD

GlaxoSmithKline plc (GSK) and Innoviva, Inc. announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone ...

GSK's three-drug inhaler wins U.S. nod for use in asthma patients

GlaxoSmithKline Plc said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler delivering three drugs at once to be ...
Pharmabiz

EU approves expanded label for once-daily Trelegy Ellipta for patients with moderate to severe COPD

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate ...
AOL

What Does a Trelegy Inhaler Cost with Medicare?

Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...